To make an appointment with a Valley cancer specialist,
please call 201-634-5339.

Other Trials

Font ++ Click to Print

MOST

"A Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy"

Key Inclusion Criteria:

  • MF Cohort: Diagnosis of MF and low-risk using DIPSS risk categorization OR intermediate-1 risk by DIPSS by reason of age alone
  • ET Cohort: Diagnosis of ET and age > 60 years OR history of thromboembolic events OR currently receiving ET-directed therapy (hydroxyurea, anagrelide, interferon, busulfan, ruxolitinib etc.)


Key Exclusion Criteria:

  • Individuals who are participating in blinded investigational drug studies
  • Individuals who are participating in Incyte investigational/interventional drug trials (company- or investigator-sponsored studies) until they have completed the 30-day end of study visit
  • Life expectancy < 6 months
  • Diagnosis of secondary acute myeloid leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, or secondary thrombocytosis


Principal Investigator: Jason Suh, M.D.

Click here for more information on MOST
 


 

Illuminate 301

A Phase 3 global, multi-center, open-label comparison of ipilimumab with and without intratumoral IMO-2125 in subjects with advanced melanoma who had confirmed disease progression while on nivolumab or pembrolizumab

Key Inclusion Criteria:
  • Metastatic Melanoma with measurable (by RECIST) Stage III (lymph node or in transit lesions) or stage IVA, IVB, or IVC disease that is accessible for injection
  • Confirmed progression during or after treatment with either Nivolumab or Pembrolizumab
    • Subjects who had adjuvant anti-PD-1 treatment are eligible if they have either disease recurrence after the end of adjuvant treatment or on-treatment disease recurrence after >/= 12 weeks of adjuvant treatment.
  • BRAF-positive tumors are eligible if they received prior treatment with a BRAF inhibitor (alone or in combination with a MEK inhibitor) or declined targeted therapy.
  • ECOG


Treatment:

  • Arm A - Ipilimumab 3 mg/kg IV weeks 1, 4, 7, and 10 -OR-
  • Arm B - IMO-2125, 8 mg/kg intratumorally weeks 1, 2, 3, 5, 8, 11, 16, 20, and 24 in combination with Ipilimumab 3mg/kg IV weeks 2, 5, 8, and 11
Principal Investigator: Jin Lee, MD

Click here for more information on Illuminate 301 

 

The Role of MicroRNA in Cancer Immunology and its Potential Application in Immunotherapy

This study is investigator-initiated and being conducted by Ganepola Ganepola, M.D., Ephraim Casper, M.D., and David Change, M.D.


Key Inclusion/Exclusions:

  • At least 18 years of age
  • About to be treated with immunotherapy drug
  • Willing and able to provide written informed consent
  • Not currently pregnant
  • No active or history of infectious diseases

 


Find a Doctor
 
View all physicians
Contact the Blumenthal Cancer Center

Have a question? Call 201-634-5339 or complete the form below. If you are experiencing a medical emergency, please call your doctor or emergency services provider.

(-
Retype the numbers below:
 Security code
----